THERAPY DOSSIER · th-8b7219d64135

Carbohydrate-derived fulvic acid (CHD-FA)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07579845 ↗NArecruiting

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

Detoxification · Inflammation · Biological Aging

Enrolment: 60 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26406424 ↗2015Reported benefit

Carbohydrate-derived fulvic acid is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens.

RatWoundSprague DawleyMaleTopicalEarly use after wound infection

Model: Traumatic wound infected with methicillin-resistant Staphylococcus aureus or multidrug-resistant Pseudomonas aeruginosa

CHD-FA accelerated healing of wounds infected with MRSA and multidrug-resistant P. aeruginosa, with improved wound surface area, histopathology and gene expression, and dampened IL-6 up-regulation at days 6 and 10.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…